BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
Raghunandan, Sharmila, Pauly, Melinda, Blum, William G, Qayed, Muna, Dhodapkar, Madhav V, Elkhalifa, Mohamed, Watkins, Benjamin, Schoettler, Michelle, Horwitz, Edwin, Parikh, Suhag, Chandrakasan, Shanmuganathan, Leung, Kathryn, Bryson, Elyse, Deeb, Laura, Kaufman, Jonathan L, Worthington-White, Diana, Alazraki, Adina, Schecter, Jordan M, Madduri, Deepu, Jackson, Carolyn C, Zudaire, Enrique, Taraseviciute-Morris, Agne, Babich, Alexander, Nesheiwat, Tonia, Vogel, Martin, Lendvai, Nikoletta, Pacaud, Lida, Williams, Kirsten M
Published in Journal for immunotherapy of cancer (01.05.2023)
Published in Journal for immunotherapy of cancer (01.05.2023)
Get full text
Journal Article
Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)
Dytfeld, Dominik, Dhakal, Binod, Agha, Mounzer, Manier, Salomon, Delforge, Michel, Kuppens, Steven, Afifi, Salma, Deraedt, William, Taraseviciute-Morris, Agne, Schecter, Jordan M., Gilbert, Jane, Yalniz, Fevzi, Florendo, Erika, Pacaud, Lida, Hungria, Vania, Usmani, Saad Z., Mateos, Maria-Victoria
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Cartitude-5: A Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Intended for Transplant
Agha, Mounzer, Dhakal, Binod, Dytfeld, Dominik, Manier, Salomon, Delforge, Michel, Kuppens, Steven, Afifi, Salma, Deraedt, William, Taraseviciute-Morris, Agne, Schecter, Jordan M, Gilbert, Jane, Yalniz, Fevzi, Florendo, Erika, Pacaud, Lida, Hungria, Vania, Usmani, Saad Z., Mateos, Maria-Victoria
Published in Transplantation and cellular therapy (01.03.2022)
Published in Transplantation and cellular therapy (01.03.2022)
Get full text
Journal Article
220 - Cartitude-5: A Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Intended for Transplant
Agha, Mounzer, Dhakal, Binod, Dytfeld, Dominik, Manier, Salomon, Delforge, Michel, Kuppens, Steven, Afifi, Salma, Deraedt, William, Taraseviciute-Morris, Agne, Schecter, Jordan M, Gilbert, Jane, Yalniz, Fevzi, Florendo, Erika, Pacaud, Lida, Hungria, Vania, Usmani, Saad Z., Mateos, Maria-Victoria
Published in Transplantation and cellular therapy (01.03.2022)
Published in Transplantation and cellular therapy (01.03.2022)
Get full text
Journal Article